The results of our meta-analysis and the analysis of Bottini (2006) both suggested that the CR indicators (such as CR and cCR) were better for NCT than for NET in both HR+ and ER+ breast cancer patients, but the difference between combination therapy and monotherapy was not significant. Here, ESR1 is linked to breast cancer.